Skip to content

Evidence

Artificial Intelligence for Neuroimaging and Musculoskeletal Radiology: Overview of Current Commercial Algorithms

SEMINARS IN ROENTGENOLOGY, 2023
Elisa R. Berson, Mariam S. Aboian, Ajay Malhotra, Seyedmehdi Payabvash

Combining semi‑quantitative rating and automated brain volumetry in MRI evaluation of patients with probable behavioural variant of frontotemporal dementia: an added value for clinical practise?

DIAGNOSTIC NEURORADIOLOGY, 2023
Sonia Francesca Calloni, Paolo Quintiliano Vezzulli, Antonella Castellano, Riccardo Leone, Silvia Basaia, Almar von Loon, Edoardo Gioele Spinelli, Giuseppe Magnani, Francesca Caso, Federica Agosta, Massimo Filippi & Andrea Falini

"I’m doing twice as much CT reporting": The impact of the lung solution at Salisbury NHS

With Dr Katharine Johnson, Consultant Radiologist at Salisbury NHS Foundation Trust and University Hospitals Southampton NHS Trust

Higher Agreement Between Readers with Deep Learning CAD Software for Reporting Pulmonary Nodules on CT

European Journal of Radiology Open
Hempel et al. Aug 2022

 

This retrospective study evaluated the impact of CAD software on the pulmonary nodule management recommendations of radiologists in a cohort of patients with incidentally detected nodules on CT. Two radiologists independently assessed 50 chest CT cases twice, unaided and aided by CAD. Readers showed a better agreement with the aid of CAD with and a significant reduction of reading time, suggesting that a dedicated CAD system for aiding in pulmonary nodule reporting may help improve the uniformity of management recommendations.

Quantib® Prostate Compared to an Expert Radiologist for the Diagnosis of Prostate Cancer on mpMRI: A Single-Center Preliminary Study

Tomography
Faiella et al. Aug 2022

 

This study evaluated the clinical utility of an Artificial Intelligence (AI) radiology solution for prostate cancer (PCa) lesions detection on multiparametric Magnetic Resonance Images (mpMRI). Prostate mpMRI exams of 108 patients were retrospectively studied. The diagnostic performance of an expert radiologist and of an inexperienced radiologist aided by AI were compared. The results demonstrated that the AI software is a very sensitive tool to use, specifically in high-risk patients (those with high PIRADS and high Gleason score).

Validation of a Deep Learning Computer Aided System for CT Based Lung Nodule Detection, Classification, and Growth Rate Estimation in a Routine Clinical Population

PLoS One
Murchison et al. May 2022

 

The deep learning algorithm of a commercially available computer assisted diagnosis system (CAD) was trained with a lung cancer screening cohort and developed for detection, classification, quantification, and growth of actionable pulmonary nodules on chest CT scans. In a retrospective cohort of a routine clinical population, the applied CAD significantly increased radiologist’s detection of actionable nodules while minimally increasing the false positive rate, suggesting it can assist in pulmonary nodule detection and management.

Robust Breast Cancer Detection in Mammography and Digital Breast Tomosynthesis Using an Annotation-Efficient Deep Learning Approach

Nature Medicine
Lotter et al. Jan 2021

 

DeepHealth’s deep-learning algorithm achieves state of the art performance in mammogram classification. The AI model was compared to 5 readers in a reader study of 131 index cancers and 154 confirmed negatives. The model showed robust and generalizable performance, reporting an Area Under the Curve (AUC) of 0.945 and outperforming all radiologists with a sensitivity 14% higher than the average radiologist sensitivity.

Validation, Comparison, and Combination of Algorithms for Automatic Detection of Pulmonary Nodules in Computed Tomography Images: The LUNA16 Challenge

Medical Image Analysis
Setio et al. Dec 2017

 

The LUNA16 challenge is an objective evaluation framework for automatic nodule detection algorithms using the largest publicly available reference database of chest CT scans. Participants developed algorithms focused on 1) the complete nodule detection track or 2) the false positive reduction track. The impact of combined systems was also investigated. The combination of these solutions achieved a sensitivity of over 95% at fewer than 1.0 false positives per scan, highlighting the potential to improve detection performance.

Disclaimers: DeepHealth Prostate is manufactured as Quantib Prostate by Quantib BV for DeepHealth Inc., DeepHealth Lung is manufactured as Veye Lung Nodules by Aidence BV for DeepHealth Inc., DeepHeath Lung Tracker is manufactured as Veye Clinic by Aidence BV for DeepHealth Inc. and DeepHealth Brain is manufactured as Quantib ND by Quantib BV for DeepHealth Inc. Not all products and functionalities are commercially available in all countries. For clearance and commercial availability in your geography of functionalities listed and compatibility with other systems, please contact us